Vitae Pharmaceuticals (VTAE) Tops Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
JMP Securities Downgrades Vitae Pharmaceuticals (VTAE) to Market Perform
August 4, 2016 7:21 AM EDTJMP Securities downgraded Vitae Pharmaceuticals (NASDAQ: VTAE) from Market Outperform to Market Perform and removed its price target (prior $10.00).
For an analyst ratings summary and ratings history on Vitae Pharmaceuticals click here. For more ratings news on Vitae Pharmaceuticals click here.
Shares of Vitae Pharmaceuticals closed at $10.29 yesterday.
... More